BIOGEN IDEC (IDP HM) stock market data APIs
€156.7224
-0.28(-0.2%)
as of March 23, 2026
Try our APIs with
free plan!
BIOGEN IDEC Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for IDP.HM.
Prev. Close
156.7224
Open
156.4468
High
156.7767
Low
156.0719
52 wk Range
99.02-169.3
Market Cap
30 257 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get BIOGEN IDEC data using free add-ons & libraries
Get BIOGEN IDEC Fundamental Data
BIOGEN IDEC Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BIOGEN IDEC News
New
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
Biogen Inc. Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment TOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Har...
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
Biogen Inc. Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE) Litifilimab was recently granted Breakthroug...
Biogen (BIIB) Valuation Check As New SMA Data And Phase 3 Plans Draw Fresh Growth Focus
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Biogen (BIIB) has put fresh attention on its spinal muscular atrophy pipeline after sharing...
Biogen Rare Disease Data And Valuation Discount Draw Investor Attention
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Biogen (NasdaqGS:BIIB) repo...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
